Abstract Body

Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants, potentially impacting their health. Here we assessed these patients safety concerns by evaluating viral reservoir size in blood and inflammatory levels in the brain. Furthermore, restriction factor (RF) expression levels and cell-associated (CA) HIV-1 RNA transcripts were assessed as potential biomarkers for predicting viral rebound.

In the HIV-STAR study, we collected peripheral blood mononuclear cells (PBMC), plasma and cerebrospinal fluid (CSF) from 11 participants at 4 time-points on-and off-treatment to assess these safety concerns and screen potential biomarkers for predicting viral rebound. Total and integrated HIV-1 DNA, CA HIV-1 RNA transcripts and restriction factors (RF) expression were measured. Markers of neuro-inflammation and neuronal injury were measured in CSF and immune activation was assessed in plasma and CSF.

Total HIV-1 DNA, integrated HIV-1 DNA and CA viral RNA transcripts did not differ pre- and post-ATI. Similarly, no significant NfL or YKL-40 increase in CSF was observed between baseline and viral rebound. Furthermore, markers of immune activation did not increase during ATI. Interestingly, RF SLFN11 and APOBEC3G increased after ATI before viral rebound was observed. Similarly, Tat-Rev transcripts were increased preceding viral rebound after interruption.

ATI did not increase viral reservoir size, nor did it reveal signs of increased neuronal injury or inflammation, suggesting that these well-monitored ATIs are safe. Elevation of Tat-Rev transcription and induced expression of RF SLFN11 and APOBEC3G after ATI prior to viral rebound indicates that these markers could be used as potential biomarkers predicting viral rebound.